Home
IVERIC bio, Inc.

IVERIC bio, Inc. Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainivericbio.com

Year Founded2007

Employees51 - 200

Annual Revenue$200M - $500M

IVERIC bio, Inc.

IVERIC bio, Inc. (including company regionals)

ivericbio.com

See more website traffic and engagement information

IVERIC bio, Inc. Revenue up to May 2026 is 200M - 500M

revenue generated by IVERIC bio, Inc. top domains

IVERIC bio, Inc. top domains revenue over 3 years

Revenue for IVERIC bio, Inc. top domains

ivericbio.com200M - 500M

See more with Sales Intelligence

Total visits to IVERIC bio, Inc.'s top domains

Understand IVERIC bio, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ivericbio.com2.2K

See more with Sales Intelligence

Avg. visit duration in IVERIC bio, Inc.'s top domains

Analyze IVERIC bio, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ivericbio.com00:00:42

See more with Sales Intelligence

Avg. pageviews on IVERIC bio, Inc.'s top domains

See how IVERIC bio, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ivericbio.com1.91

See more with Sales Intelligence

IVERIC bio, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by IVERIC bio, Inc.

These are the website technologies, by industry, used by IVERIC bio, Inc. top domains

Advertising (6)

DoubleClick

Content Management System (3)

WordPress

Marketing (3)

Google Marketing Platform

Conversion & Analytics (2)

Google Analytics

More Technologies

8

See all

News & Signals from IVERIC bio, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsShah leaves Iveric Bio Inc. as Chief Regulatory & Product Strategy Officer.Dr. Shah joins Oculis from Iveric Bio where he served as Chief Regulatory & Product Strategy Officer and led the successful approval of Izervay(R) for Geographic Atrophy in the U.S.

NewsIveric Bio Inc. acquired Izervay for $5.9B on Jan 1st '23.Izervay(TM) was acquired by Iveric Bio and sold to Astellas for $5.9 billion in 2023.

NewsIveric Bio Inc. launched fresh awareness campaign on Aug 21st '23.Astellas' recent acquisition, Iveric Bio, has launched a fresh awareness campaign for a disease it recently received FDA approval to treat.